Prevalence of the Academic Research Consortium for High Bleeding Risk Criteria and Prognostic Value of a Simplified Definition
- 25 August 2020
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 84 (9), 1560-1567
- https://doi.org/10.1253/circj.cj-20-0395
Abstract
Background:The Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria have been suggested as the standard definition of HBR. However, the prevalence of individual criteria and their prognostic value for long-term bleeding events after percutaneous coronary intervention are scarcely studied. Methods and Results:The study population comprised 1,193 patients treated with everolimus-eluting stents between 2010 and 2011. Data on all 17 major and minor criteria of the ARC-HBR definition were retrospectively collected, and applied to this study population. Major bleeding was defined as the occurrence of a BARC type 3 or 5 bleeding event. A simplified definition was developed by excluding the low-frequency criterion, and the prognostic value was assessed by a receiver-operating characteristic curve. Mean follow-up was 2,996±433 days and there were 656 HBR patients (55.0%). The cumulative incidence of major bleeding was significantly higher in the HBR group than in the non-HBR group (16.2% vs. 5.7% at 8 years, PConclusions:Some risk criteria of the ARC-HBR definition are observed infrequently. Our simplified definition identified patients with long-term bleeding risk as successfully as the original definition.Keywords
This publication has 28 references indexed in Scilit:
- Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trialThe Lancet, 2018
- Duration of dual antiplatelet therapy following drug‐eluting stent implantation: A systemic review and meta‐analysis of randomized controlled trials with longer follow upCatheterization and Cardiovascular Interventions, 2017
- Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trialsThe Lancet, 2017
- Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting StentsJournal of the American College of Cardiology, 2016
- Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding RiskThe New England Journal of Medicine, 2015
- Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial InfarctionJournal of the American College of Cardiology, 2015
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsThe New England Journal of Medicine, 2014
- World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCINature Reviews Cardiology, 2014
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- Clinical End Points in Coronary Stent TrialsCirculation, 2007